摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

7-十八酮 | 18277-00-4

中文名称
7-十八酮
中文别名
——
英文名称
7-octadecanone
英文别名
octadecan-7-one
7-十八酮化学式
CAS
18277-00-4
化学式
C18H36O
mdl
MFCD00049085
分子量
268.483
InChiKey
HHQOJAVJSCPMAC-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

物化性质

  • 熔点:
    51.5°C (estimate)
  • 沸点:
    336.64°C (estimate)
  • 密度:
    0.8453 (estimate)

计算性质

  • 辛醇/水分配系数(LogP):
    7.6
  • 重原子数:
    19
  • 可旋转键数:
    15
  • 环数:
    0.0
  • sp3杂化的碳原子比例:
    0.944
  • 拓扑面积:
    17.1
  • 氢给体数:
    0
  • 氢受体数:
    1

安全信息

  • 海关编码:
    2914190090

SDS

SDS:fac07ded6404c5bc592d78b7bf0e2ca3
查看

上下游信息

  • 上游原料
    中文名称 英文名称 CAS号 化学式 分子量

反应信息

  • 作为反应物:
    描述:
    7-十八酮溴乙酸乙酯甲苯 作用下, 生成 3-hexyl-3-hydroxy-tetradecanoic acid
    参考文献:
    名称:
    Breusch; Baykut, Chemische Berichte, 1957, vol. 90, p. 526,528,531
    摘要:
    DOI:
  • 作为产物:
    描述:
    1-碘己烷锌铜偶乙酸乙酯甲苯 作用下, 生成 7-十八酮
    参考文献:
    名称:
    Breusch; Baykut, Chemische Berichte, 1953, vol. 86, p. 684,686
    摘要:
    DOI:
点击查看最新优质反应信息

文献信息

  • Development of a convoluted polymeric nanopalladium catalyst: α-alkylation of ketones and ring-opening alkylation of cyclic 1,3-diketones with primary alcohols
    作者:Yoichi M.A. Yamada、Yasuhiro Uozumi
    DOI:10.1016/j.tet.2007.05.071
    日期:2007.8
    A novel solid-phase catalyst of palladium nanoparticles, nano-Pd-V, was prepared from PdCl2 with main-chain viologen polymers via complexation and reduction. This insoluble nanocatalyst nano-Pd-V efficiently promoted α-alkylation of ketones with primary alcohols in the presence of Ba(OH)2·H2O under atmospheric conditions without organic solvents. The nano-Pd-V catalyst was reused without loss of catalytic
    通过PdCl 2与主链紫精聚合物的络合和还原反应,制备了一种新型的钯纳米颗粒固相催化剂:Nano-Pd-V 。在不存在有机溶剂的大气条件下,在Ba(OH)2 ·H 2 O的存在下,这种不溶的纳米催化剂纳米Pd-V有效地促进了伯醇与酮的α-烷基化。纳米Pd-V催化剂可以重复使用而不会损失催化活性。纳米Pd-V催化剂还催化了环1,3-二酮与伯醇的开环烷基化反应。
  • Metal-Dependent Reaction Tuning with Cyclopentylmetal Reagents: Application to the Asymmetric Synthesis of (+)-α-Conhydrine and (<i>S</i>)-2-Cyclopentyl-2-phenylglycolic Acid
    作者:Siddharth Roy、Anubha Sharma、Soumyaditya Mula、Subrata Chattopadhyay
    DOI:10.1002/chem.200801603
    日期:2009.2.2
    The reaction of halocyclopentane organometallic reagents can be tuned by the choice of metal (see scheme). Cyclopentylmagnesium bromide reduces aldehydes and ketones to the corresponding alcohols. However, in the presence of ZnCl2, normal Grignard addition to the ketones gives tertiary alcohols with complete diastereoselectivity. These protocols were used in the asymmetric synthesis of two medicinally
    调整:卤环戊烷有机金属试剂的反应可通过选择金属来调整(参见方案)。环戊基溴化镁将醛和酮还原为相应的醇。然而,在存在ZnCl 2的情况下,向酮中常规的格利雅(Grignard)加成会产生具有完全非对映选择性的叔醇。这些规程用于两种医学上重要的化合物的不对称合成。
  • Transition Metal Cluster Catalyst
    申请人:Uozumi Yasuhiro
    公开号:US20090299101A1
    公开(公告)日:2009-12-03
    The present invention provides a catalyst, which has enough catalytic activity as a transition metal particle catalyst including platinum family and the like, is easily separable from products, is reusable and is easily prepared. To prepare the transition metal cluster catalyst of the present invention, an insoluble complex is prepared by forming a complex between a polymer with nitrogen-containing group, such as pyridinium and ammonium group in the principal chain, and a later transition metal compound; and then reducing the complex with a reductant. The transition metal forms clusters, which are stabilized by the polymers. Namely, the present invention is a transition metal cluster catalyst, wherein transition metal clusters are supported by a polymer, which is obtained by reduction reaction of a complex of a transition metal and a polymer with nitrogen-containing group. The transition metal cluster catalyst of the present invention is an extremely useful catalyst for oxidation, reduction, cross-coupling, Heck reaction, alkylation reaction and the like.
    本发明提供了一种催化剂,其具有足够的催化活性,如铂系族等过渡金属粒子催化剂,易于与产物分离,可重复使用且易于制备。为了制备本发明的过渡金属团簇催化剂,首先通过在主链中形成含氮基团的聚合物(如吡啶基和铵基)与后续的过渡金属化合物形成复合物来制备不溶性复合物;然后用还原剂还原该复合物。过渡金属形成团簇,这些团簇由聚合物稳定。换句话说,本发明是一种过渡金属团簇催化剂,其中过渡金属团簇由含氮基团的聚合物与过渡金属复合物的还原反应得到。本发明的过渡金属团簇催化剂对氧化、还原、交叉偶联、Heck反应、烷基化反应等非常有用。
  • [EN] HYDROCARBON SYNTHESIS METHODS, APPARATUS, AND SYSTEMS<br/>[FR] PROCÉDÉS, APPAREIL ET SYSTÈMES DE SYNTHÈSE D'HYDROCARBURES
    申请人:MCNEFF CLAYTON V
    公开号:WO2014008355A1
    公开(公告)日:2014-01-09
    Embodiments of the invention include apparatus and systems for hydrocarbon synthesis and methods regarding the same. In an embodiment, the invention includes a process for creating a hydrocarbon product stream comprising reacting a reaction mixture in the presence of a catalyst inside of a reaction vessel to form a product mixture, the reaction mixture comprising a carbon source and water. The temperature inside the reaction vessel can be between 450 degrees Celsius and 600 degrees Celsius and the pressure inside the reaction vessel can be above supercritical pressure for water. In an embodiment, the invention includes an extrusion reactor system for creating a hydrocarbon product stream. The temperature inside the extrusion reactor housing between 450 degrees Celsius and 600 degrees Celsius. Pressure inside the reaction vessel can be above supercritical pressure for water. Other embodiments are also included herein.
    本发明的实施例包括用于合成碳氢化合物的设备和系统以及相关方法。在一种实施例中,本发明包括一种用于创建碳氢化合物产品流的过程,其中在反应容器内,在催化剂的存在下,反应混合物以形成产物混合物,反应混合物包括碳源和水。反应容器内的温度可在450摄氏度至600摄氏度之间,反应容器内的压力可高于水的超临界压力。在一种实施例中,本发明包括一种挤出反应器系统,用于创建碳氢化合物产品流。挤出反应器壳体内的温度在450摄氏度至600摄氏度之间。反应容器内的压力可高于水的超临界压力。本发明还包括其他实施例。
  • Cyclic dinucleotides as anticancer agents
    申请人:BRISTOL-MYERS SQUIBB COMPANY
    公开号:US10744150B2
    公开(公告)日:2020-08-18
    The present invention is directed to compounds of the formulae I, II and III as shown below wherein all substituents are defined herein, as well as pharmaceutically acceptable compositions comprising compounds of the invention and methods of using said compositions in the treatment of various disorders.
    本发明涉及如下式 I、II 和 III 所示的化合物 其中所有取代基均在本文中定义,以及包含本发明化合物的药学上可接受的组合物和使用所述组合物治疗各种疾病的方法。
查看更多